MAXIMIZING THE KNOWLEDGE GAINED FROM CALIFORNIA SENATE BILL 27 (360G-Wellcome-211493_A_18_Z)

£254,330

On January 1, 2018, California enacted Senate Bill 27 (SB27), first-of-its-kind and potentially precedent-setting legislation, which will require a veterinarian’s prescription for use of antimicrobial drugs and ban non-therapeutic antimicrobial uses for routine disease prevention and growth promotion in livestock. To assess the effectiveness of this important legislation at reducing antimicrobial resistant bacterial infections in humans, we propose the following specific aims: Aim 1. Quantify the effect of SB27 on E. coli, Campylobacter and Salmonella resistance rates from retail meat. Aim 2. Estimate the proportion of human Campylobacter, Salmonella, and extraintestinal pathogenic E. coli infections caused by strains of food-animal origin in California. Aim 3. Characterize the effect of SB27 on the antimicrobial susceptibility of Campylobacter, Salmonella, and extraintestinal E. coli infections caused by strains of food-animal origin in California. Implementation of SB27 provides a unique natural experiment to assess the effectiveness of restrictive agricultural antimicrobial-use policies at reducing antimicrobial-resistant human infections. The proposed research will have a positive impact by prospectively measuring the effect of this policy on the antimicrobial susceptibility of E. coli (an important colonizing opportunistic pathogen) and Campylobacter and Salmonella (two frank foodborne pathogens) and thereby maximizing the information gained from this singular opportunity

Where is this data from?

This data was originally published by The Wellcome Trust. If you need to report a problem in the data please contact The Wellcome Trust directly, see their GrantNav publisher page for more information.

Grant Details

Amount Awarded 254330
Applicant Surname Aanensen
Approval Committee DRI Epidemiology and Surveillance Panel
Award Date 2018-09-30T00:00:00+00:00
Financial Year 2017/18
Grant Programme: Title Discretionary award – DRI
Internal ID 211493/A/18/Z
Lead Applicant Prof David Aanensen
Partnership Value 254330
Planned Dates: End Date 2020-09-01T00:00:00+00:00
Planned Dates: Start Date 2018-09-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South East